Monoclonal antibody Hu8H9 I-131 - Y-mAbs Therapeutics

Drug Profile

Monoclonal antibody Hu8H9 I-131 - Y-mAbs Therapeutics

Alternative Names: 131I-Hu8H9 (B7-H3)

Latest Information Update: 06 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Y-mAbs Therapeutics
  • Class Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD antigen modulators; Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Soft tissue sarcoma

Most Recent Events

  • 04 Oct 2016 Preclinical trials in Soft tissue sarcoma in USA (Parenteral)
  • 14 Oct 2014 Y-mAbs Therapeutics in-licenses anti-B7-H3 antibody programme from Memorial Sloan Kettering Cancer Center
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top